Open a new door for patients with heart failure

Chen Song

The year of birth : January 1984

joined the party time : 2021

]

Occupation : The co -founder and technical director of Wuhan Wei Ke Medical Technology Co., Ltd.

Get honor : 2020 Hubei Province's 7th provincial employee Technological Innovation Achievement Reward Third Award, 2020 Hubei Provincial Science and Technology Award Science and Technology Progress Award II, 2021 Medical Science and Technology Innovation Advanced Individual, 2021 High -tech Industry High -tech Outstanding Workers, 2021 National Multinational Technology Innovation Competition Outstanding Award The winner

Recently, in Wuhan We Ke Medical Technology Co., Ltd. (hereinafter referred to as \"Wei Ke Medical\") production workshop, workers are producing a healing to treat heart failure The \"D-SHANT atrium diversion\" product, \"dense\" is its biggest feature, a non-riveting dual-disk buckle structure composed of dozens of nickel-titanium alloy wires with dozens of hair filaments The waist forms a fixed diameter and height.

\"This is the first domestic atrium downsometer product, without any reference. Every fine adjustment has undergone countless repeated experiments.\" As the earliest domestic engineer engaged in research and development of cardiac intervention medical device products in China Chen Song has rich experience in research and development of medical device products, but it is still a difficult thing to develop a medical device product from scratch.

From 2018, the research and development of the \"D-SHANT atrium shunt\" lasted one year, from the selection, weaving, and heat treatment of raw materials to processing, and the overall process process exceeded 30. Among them, only on the problem of \"how to maintain the balance between the stability of the aperture and the compliance\", Chen Song led the R \u0026 D team to design more than 10 specifications. In the end, the support of the waist support is enhanced by improving the weaving process, and the unilateral eccentric rivet design achieves the recyclable structure of the product.

This is currently the only diversion device in the world that can be recycled and intervene in secondary intervention, that is, at any time after surgery, once the patient's blood flow has a problem, it can still use minimally invasive this to take this through minimally invasive this. The device is taken out. This is a \"retreat\" treatment, and the cost is much lower than that of traditional heart failure equipment.

Chen Song is in the production workshop. Reporter Hu Zanwei

The product design has completed how to produce in batches, which has become another problem in front of Chen Song. All the weaving processes of this product need to be done manually. However, even the most skilled workers to make a atrium downtale, it takes nearly 3 hours. \"Some things are unable to replace the machineEssence From the beginning, we have to cultivate workers. \"

Recruiting people is not easy. Minimally involved medical devices and three types of high -risk implants are very rare in Wuhan and even central China. There are no ready -made talents. The introduction of a group of employees in Suzhou and other places, and then through the \"old -fashioned\" model, cultivated a group of mature workers. Chen Song's words are difficult to hide pride: \"From 0 to 1 to 100, Wei Ke Medical has batch production ability. \"

In April 2020, the D-SHANT atrium diversion completed the first human body implantation in China, marking that China has achieved zero breakthrough in this field. The home center has carried out multi -center registration clinical verification. It is expected to complete the clinical trial entry work by the end of this year, and it is approved for registration in 2024.

Chen Song said that the development of medical device products is a long and difficult road. In the face of obstacles and setbacks, the only solution is innovation, attempt and persistence.

[Edit: Hou Fangyu]

For more exciting content, please download \"Da Wuhan\" in major application markets. Client.